Somyata Saxena

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

Robert J. Amato, J. Jac, S. Giessinger et al. · Cancer · 2009 · 202 citations · Full text

Medicine, Oncology, Pharmacology +17

Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α)

Robert J. Amato, William Shingler, Madusha Goonewardena et al. · Journal of Immunotherapy · 2009 · 78 citations

Medicine, Immunology, Oncology +17

Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial

Robert J. Amato, William Shingler, Stuart Naylor et al. · Clinical Cancer Research · 2008 · 62 citations

Medicine, Immunology, Oncology +17

A Phase II Trial of Intrapatient Dose-Escalated Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Robert J. Amato, Jim Zhai, J. P. Willis et al. · Clinical Genitourinary Cancer · 2012 · 39 citations

Medicine, Oncology, Pharmacotherapy +16

Epithelial Cell Adhesion Molecule-positive Circulating Tumor Cells as Predictive Biomarker in Patients With Prostate Cancer

Robert J. Amato, V. Melnikova, Yujian Zhang et al. · Urology · 2013 · 30 citations

Medicine, Oncology, Urology +14